Zogenix wants to help the pain go away faster. The biopharmaceutical company is developing and commercializing central nervous system (CNS) and therapeutic pain medications. The company's sole marketed product, Sumavel DosePro received FDA approval for in 2009. The drug combines the company's DosePro needle-free drug delivery technology with migraine drug sumatriptan. Patients can self-administer the drug subcutaneously for rapid relief of acute migraines and cluster headaches. Its late-stage candidate, ZX002, is an oral controlled-release formulation of hydrocodone, used for the treatment of chronic pain. Chairman Cam Garner founded Zogenix in 2006. The company went public through an IPO in 2010.